iX Biopharma

The patent, which is the second notice of allowance from the USPTO in recent months, is expected to expire no earlier than October 2030.

The agreement marks iX Biopharma’s official entry into the high-growth Australian cannabis market, which is expected to grow from US$0.04 billion in 2020 to US$1.23 billion in 2024.

iX Biopharma has entered into a 10-year licensing agreement with Yiling Pharmaceutical in China for the licensing, supply, and distribution of Wafesil, a fast-dissolving sublingual sildenafil wafer for the treatment of male erectile dysfunction.

SINGAPORE (Dec 5): iX Biopharma has been awarded a cannabis manufacture license from the Australian Office of Drug Control to manufacture and supply extracts and tinctures of cannabis and cannabis resins.

SINGAPORE (May 9): iX Biopharma announced 3Q19 earnings of $7.8 million, compared to a loss of $3.9 million in 3Q18, due to a one-off gain from the disposal of a subsidiary.

SINGAPORE (Feb 18): iX Biopharma is selling Chemical Analysis, its laboratory testing business in Australia, to Eurofins Australia New Zealand Holding for A$12.5 million ($12 million).  

SINGAPORE (Feb 12): Specialty pharmaceutical and nutraceutical firm iX Biopharma has reported a net loss of $3.6 million in 2Q19, an increase of 11% compared to a net loss of $3.2 million in 2Q18.

SINGAPORE (Feb 1): The Edge Singapore has assembled the annual portfolio of 10 stocks, done in conjunction with the Lunar New Year.

SINGAPORE (June 19): iX Biopharma says the Australia’s regulatory authority, Therapeutic Goods Administration (TGA), has given the go-ahead for the use of Wafesil to treat of male erectile dysfunction in the country.

SINGAPORE (May 9): Specialty pharmaceutical company iX Biopharma recorded a net loss of $4.3 million in 3Q18, against a net loss of $2.9 million in 3Q17.